WASHINGTON — There is «a substantial reason to believe» that Rep. Chris Collins violated federal law
by touting the stock of an obscure Australian biotech firm based on inside information, while also possibly breaking House ethics rules
by persuading National Institutes of
Health officials to meet with a staffer from that company.